Eisai Opens New Solid Dose Global Manufacturing Line for Antiepileptic Agent Fycompa(R) at Its Production Plant in Hatfield, U.K.
- Ceremony attended by Rt Hon. David Willetts, Minister of State for Universities and Science -
Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.K. manufacturing subsidiary Eisai Manufacturing Ltd. (EML) situated within the company's European Knowledge Centre (EKC), has received a license (marketing authorization type II variation: addition of manufacturing site) from the European regulatory authorities for solid dose manufacturing of the antiepileptic agent Fycompa(R) (perampanel), a first-in-class AMPA receptor antagonist discovered and developed in-house, at its Hatfield production plant. Eisai celebrated this occasion with a ceremony to mark the official opening of a new Fycompa manufacturing line.
Positioning the Hatfield plant as a global supply hub for Fycompa, Eisai plans to obtain authorization from the regulatory authorities in other countries to use the site to manufacture the drug for supply in each respective market.
The opening ceremony was attended by the Rt Hon. David Willetts, Minister of State for Universities and Science, who expressed his hopes that Eisai, whose activities in the U.K are an excellent example of the continued success of the country's life science industry, will continue its endeavors toward the creation of innovative new medicines that bring benefits to patients.
Discovered and developed at Eisai's research laboratories in Japan and the U.K., Fycompa was approved in the European Union (EU) ahead of other regions in the world for use as an adjunctive treatment for partial onset seizures, with or without secondarily generalized seizures, in patients aged 12 years and older. It was first launched globally in the U.K. earlier this month, followed by Germany, Austria and Denmark.
Eisai established the EKC, which integrated the company's discovery research, clinical development, production, marketing and European headquarters functions one site, in Hertfordshire in the U.K. in June 2009 with the aim to expand its business operations across Europe. At present, the facility plays an even more important role as the regional headquarters for Eisai's Europe, Middle East, and Africa (EMEA) business.
The Hatfield plant, located within the grounds of the EKC, has up until now served predominantly as a manufacturing site for the production of pharmaceuticals for the European market, however, the EU manufacturing license for the new facility marks the first step in Eisai's plan to obtain manufacturing licenses from the regulatory authorities in other countries and regions as it seeks to expand operations and establish the facility as a site for the global supply of Fycompa.
By strengthening its U.K. value chain, which encompasses discovery, production and marketing, Eisai will enhance its presence in the EMEA region, thereby making contributions to patients on a global scale.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2012 JCN Newswire. All rights reserved. www.japancorp.net